Primary lymphocytes as predictors for species differences in cytotoxic drug sensitivity

Toxicology in Vitro

Volumn 21, Issue 6, 2007, Pages 1174-1181

  Hassan, S B ^a   Haglund, C ^a   Aleskog A ^a   Larsson, R ^a   Lindhagen, E ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CFU GM assay; FMCA; Haematotoxicity; Primary lymphocytes; Species differences

Indexed keywords

ANTHRACYCLINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CISPLATIN; CORTICOSTEROID; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MELPHALAN; PACLITAXEL; PREDNISOLONE; PROTEASOME INHIBITOR; TIOGUANINE; TOPOTECAN;

ANIMAL CELL; ARTICLE; BLOOD; BLOOD TOXICITY; CHEMOSENSITIVITY; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PREDICTOR VARIABLE; RAT; RODENT; SPECIES COMPARISON; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; DOGS; FEMALE; FLUOROMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED BALB C; RATS; RATS, INBRED STRAINS; SPECIES SPECIFICITY; TOXICITY TESTS;

CANIS FAMILIARIS; RATTUS; RODENTIA;

EID: 34547761275     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2007.03.009     Document Type: Article

References (27)

1. Bradley T.R., and Metcalf D. The growth of mouse bone marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci. 44 (1966) 287-299
2. Clark D.L., Andrews P.A., Smith D.D., DeGeorge J.J., Justice R.L., and Beitz J.G. Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin. Cancer Res. 5 (1999) 1161-1167
3. Collins J.M., Grieshaber C.K., and Chabner B.A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82 (1990) 1321-1326
4. Csoka K., Larsson R., Tholander B., Gerdin E., de la Torre M., and Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol. Oncol. 54 (1994) 163-170
5. Dal Negro G., Vandin L., Bonato M., Repeto P., and Sciuscio D. A new experimental protocol as an alternative to the colony-forming unit-granulocyte/macrophage (CFU-GM) clonogenic assay to assess the haematotoxic potential of new drugs. Toxicol. In Vitro 20 (2006) 750-756
6. DeGeorge J.J., Ahn C.H., Andrews P.A., Brower M.E., Giorgio D.W., Goheer M.A., Lee-Ham D.Y., McGuinn W.D., Schmidt W., Sun C.J., and Tripathi S.C. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother. Pharmacol. 41 (1998) 173-185
7. Erickson-Miller C.L., May R.D., Tomaszewski J., Osborn B., Murphy M.J., Page J.G., and Parchment R.E. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother. Pharmacol. 39 (1997) 467-472
8. Fridborg H., Nygren P., and Larsson R. Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anticancer Drugs 6 (1995) 64-69
9. Fridborg H., Jonsson E., Nygren P., and Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur. J. Cancer 35 (1999) 424-432
10. Fuse E., Kobayashi S., Inaba M., Suzuki H., and Sugiyama Y. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J. Natl. Cancer Inst. 86 (1994) 989-996
11. Gribaldo L. Haematotoxicology: scientific basis and regulatory aspects. Altern. Lab. Anim. 30 Suppl. 2 (2002) 111-113
12. Gribaldo L., Casati S., Castoldi A.F., and Pessina A. Comparison of in vitro drug-sensitivity of human granulocyte-macrophage progenitors from two different origins: umbilical cord blood and bone marrow. Exp. Hematol. 27 (1999) 1593-1598
13. Hovstadius P., Larsson R., Jonsson E., Skov T., Kissmeyer A.M., Krasilnikoff K., Bergh J., Karlsson M.O., Lonnebo A., and Ahlgren J. A phase I study of CHS 828 in patients with solid tumor malignancy. Clin. Cancer Res. 8 (2002) 2843-2850
14. Larsson R., and Nygren P. A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res. 9 (1989) 1111-1119
15. Larsson R., Kristensen J., Sandberg C., and Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 50 (1992) 177-185
16. Lindhagen E., Vig Hjarnaa P.-J., Friberg L.E., Latini S., and Larsson R. Pharmacodynamic differences between species exemplified by the novel anticancer agent CHS 828. Drug Develop. Res. 61 (2004) 218-226
17. Malerba I., Casati S., Diodovich C., Parent-Massin D., and Gribaldo L. Inhibition of CFU-E/BFU-E and CFU-GM colony growth by cyclophosphamide, 5-fluorouracil and taxol: development of a high-throughput in vitro method. Toxicol. In Vitro 18 (2004) 293-300
18. Masubuchi N., May R.D., and Atsumi R. A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay. Clin. Cancer Res. 10 (2004) 6722-6731
19. Moneta D., Geroni C., Valota O., Grossi P., de Jonge M.J., Brughera M., Colajori E., Ghielmini M., and Sessa C. Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3′-deamino-3′-aziridinyl-4′- methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation. Eur. J. Cancer 39 (2003) 675-683
20. Nagami K., Kawashima Y., Kuno H., Kemi M., and Matsumoto H. In vitro cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes and neutrophils. J. Toxicol. Sci. 27 (2002) 191-203
21. Parchment R.E., Gordon M., Grieshaber C.K., Sessa C., Volpe D., and Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann. Oncol. 9 (1998) 357-364
22. Parent-Massin D.M., Sensebe L., Leglise M.C., Guern G., Berthou C., Riche C., and Abgrall J.F. Relevance of in vitro studies of drug-induced agranulocytosis: Report of 14 cases. Drug Saf. 9 (1993) 463-469
23. Pessina A., Albella B., Bueren J., Brantom P., Casati S., Gribaldo L., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Sibiril Y., and Van Den Heuvel R. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol. In Vitro 15 (2001) 729-740
24. Pessina A., Albella B., Bayo M., Bueren J., Brantom P., Casati S., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Schoeters G., Sibiril Y., Van Den Heuvel R., and Gribaldo L. Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics. Toxicol. Sci. 75 (2003) 355-367
25. Rickardson L., Fryknas M., Dhar S., Lovborg H., Gullbo J., Rydaker M., Nygren P., Gustafsson M.G., Larsson R., and Isaksson A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer 93 (2005) 483-492
26. Rooseboom M., Commandeur J.N., and Vermeulen N.P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 56 (2004) 53-102
27. Thompson J., Stewart C.F., and Houghton P.J. Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta 1400 (1998) 301-319